Leqvio FDA Approval

Leqvio® go-to-market model: systems engagement, complemented by broad HCP education with CRM sales team Systems of care Targets customers ■ ~200 prioritized systems Engagement approach LeqvioⓇ pathway ■ 45% currently prioritize ASCVD² ■ Cross-functional teams engaged with key systems stakeholders ■ Aim to ensure protocols in place to identify and manage ASCVD patients not at goal May leverage existing buy-and-bill infrastructure or refer to an alternative injection center ☐ HCPs Representing ~60% of NBRx volume1 Leveraging strong commercial CRM footprint Highlighting unmet need and raise importance of LDL-C May administer in-office or refer to alternative injection center ASCVD - Atherosclerotic Cardiovascular Disease HCP - Healthcare Professional CV Cardiovascular CRM Cardiovascular, Renal, Metabolic LDL-C - Low Density Lipoprotein Choletsterol 1. Data on file. 2. Data on file 23 Leqvio FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine

View entire presentation